List of Excipients in Branded Drug MICAFUNGIN IN SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	ANHYDROUS CITRIC ACID
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	SODIUM CHLORIDE
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	TRISODIUM CITRATE DIHYDRATE
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	WATER

Micafungin in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 15, 2026

Micafungin in sodium chloride is an injectable echinocandin opportunity centered on ready-to-administer delivery, stability, hospital workflow, and differentiated packaging rather than new pharmacology. The U.S. reference product, Mycamine, is supplied as a lyophilized powder requiring reconstitution and dilution. A premixed micafungin sodium injection in 0.9% sodium chloride could reduce preparation steps, support pharmacy automation, and compete on total administration cost.

The commercial opportunity is strongest in hospital-use presentations, pediatric dosing flexibility, low-volume bags, light-protective packaging, and extended-use stability. The principal regulatory pathway for a generic micafungin product is an abbreviated new drug application, or ANDA, rather than a biosimilar application.

What is micafungin in sodium chloride?

Micafungin sodium is an intravenous echinocandin antifungal used for candidemia, invasive candidiasis, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem-cell transplant patients. The FDA-approved reference product is Mycamine, marketed by Astellas Pharma US.[1]

The commercial formulation concept has two versions:

Formulation concept	Typical presentation	Commercial position
Lyophilized vial	50 mg or 100 mg micafungin sodium	Current reference-product architecture
Reconstituted hospital preparation	Vial diluted into 0.9% sodium chloride or dextrose 5%	Requires pharmacy manipulation
Ready-to-administer premix	50 mg or 100 mg in sodium chloride injection	Workflow and compounding reduction
Small-volume concentrated solution	Dose in a lower-volume infusion container	Pediatric and fluid-restricted use
Pharmacy bulk or multi-dose concept	Larger institutional format	Limited by sterility, preservative, and regulatory constraints

Micafungin is administered intravenously because its oral bioavailability is inadequate for systemic treatment. Sodium chloride is primarily a vehicle and tonicity agent in a premixed product. It is not the active pharmaceutical ingredient.

What excipients are used in the approved micafungin formulation?

The Mycamine vial contains micafungin sodium and inactive ingredients associated with the lyophilized formulation, including lactose. The product is reconstituted with sterile water for injection and diluted in 0.9% sodium chloride injection or dextrose 5% in water before administration.[1]

The excipient strategy for a ready-to-use product should be narrower than the strategy for the lyophilized vial. A commercially attractive formulation would normally seek to use:

• Water for injection as the primary solvent.
• Sodium chloride for isotonicity.
• A controlled pH system or pH adjustment, if required for stability.
• No antimicrobial preservative for single-dose hospital use.
• No new surfactant unless forced by solubility, adsorption, or container-interaction data.
• Low extractables and leachables packaging suitable for prolonged intravenous contact.

A premixed product should avoid unnecessary excipients because each added component creates new compatibility, toxicology, labeling, and manufacturing requirements.

Why lactose may not be needed in a sodium chloride premix

Lactose has a functional role in the lyophilized reference presentation, but it may not be necessary in a liquid premix. Removing it could provide several commercial advantages:

1. Fewer inactive ingredients.
2. Lower risk of excipient-related differentiation disputes.
3. Reduced particulate or precipitation risk during dilution.
4. Simpler labeling for hospitals and pharmacists.
5. Easier adaptation to a ready-to-administer bag or vial.

The development risk is that the liquid formulation may have lower chemical stability than the freeze-dried product. A premix therefore needs a complete stability package covering assay, degradation products, particulate matter, color, pH, sterility, container closure integrity, and infusion compatibility.

What formulation attributes matter most for micafungin sodium chloride products?

The key technical challenge is maintaining micafungin stability in an aqueous environment through manufacturing, storage, transport, and administration.

pH control

Micafungin formulation development should map degradation across pH, ionic strength, temperature, and oxygen exposure. The target pH should balance chemical stability, infusion tolerability, and container compatibility.

A highly buffered product may create problems if the buffer changes the micafungin degradation pathway or interacts with the container. A lightly buffered or pH-adjusted sodium chloride formulation may provide a more defensible commercial design if it delivers adequate shelf life.

Light protection

The Mycamine label requires protection from light during storage and handling.[1] A premixed product should use an overwrap, amber or opaque container, light-protective secondary packaging, or a validated administration cover. Light protection is both a technical requirement and a product-design opportunity.

Packaging claims could include:

• Ready-to-administer, light-protected infusion.
• Reduced pharmacy preparation.
• Validated in-use stability after removal from refrigeration.
• Compatibility with automated dispensing and compounding systems.

Container selection

Candidate systems include glass bottles, multilayer polyolefin bags, cyclic olefin polymer containers, and other parenteral-compatible systems. Selection should consider:

• Micafungin adsorption to the container.
• Extractables and leachables.
• Oxygen transmission.
• Moisture transmission.
• Closure integrity.
• Compatibility with standard infusion sets.
• Resistance to overwrap and transport stress.
• Ease of barcode scanning and automated inventory handling.

A bag can reduce breakage and facilitate direct connection to an infusion set. A ready-to-use vial may provide better dose flexibility and lower fill-volume requirements. The commercial choice depends on whether the product targets adult inpatient use, pediatrics, oncology centers, or outpatient infusion providers.

Dilution and admixture compatibility

The reference label identifies 0.9% sodium chloride and dextrose 5% as compatible diluents under specified conditions.[1] A premixed sodium chloride product should establish compatibility with common administration materials and infusion devices, including polyvinyl chloride and non-PVC systems where commercially relevant.

The development package should assess:

• Precipitation and visible particles.
• Subvisible particles.
• Sorption and recovery.
• Assay after simulated administration.
• Compatibility with filters.
• Compatibility with common infusion pumps.
• Stability after connection to administration sets.
• Co-administration restrictions.

The product should not imply compatibility with other intravenous drugs without supporting data.

What commercial opportunities exist for a micafungin sodium chloride premix?

Ready-to-administer hospital product

The strongest opportunity is a ready-to-administer infusion that eliminates vial reconstitution and pharmacy dilution. Hospitals may value the product because it can reduce:

• Pharmacy preparation time.
• Sterile compounding workload.
• Reconstitution errors.
• Wastage from partially used vials.
• Staff exposure to compounding activities.
• Delays in first-dose administration.

The product would compete on total cost of care rather than acquisition price alone. A higher unit price may be acceptable if preparation savings, waste reduction, and faster administration are documented.

Pediatric and fluid-restricted presentations

Micafungin is used in pediatric and neonatal settings, where infusion volume can matter. A lower-volume sodium chloride presentation, if supported by stability and infusion tolerability data, could address:

• Neonatal intensive care.
• Pediatric hematopoietic stem-cell transplantation.
• Patients with fluid restrictions.
• Home or outpatient infusion protocols.

The dose flexibility must be balanced against the risk of dosing errors. A single-concentration product can simplify administration, while multiple strengths can reduce withdrawal and dilution steps.

Closed-system and pharmacy automation

A ready-to-use container compatible with automated dispensing cabinets and pharmacy robotics could create a differentiated institutional product. Commercial features may include:

• Machine-readable barcodes.
• Standardized dose strengths.
• Tamper-evident overwraps.
• Unit-dose packaging.
• Serialized hospital supply-chain data.
• Compatibility with common automated compounding platforms.

These features are not substitutes for formulation patents, but they can support procurement differentiation and customer retention.

Contract manufacturing and regional licensing

Micafungin sodium chloride products could be developed through:

• An ANDA sponsor with a contract sterile manufacturer.
• A regional licensing arrangement.
• A hospital-focused generic portfolio transaction.
• A co-development agreement with a parenteral packaging specialist.
• A supply agreement with an automated compounding or infusion-system company.

The highest-value partner is likely to bring sterile fill-finish capacity, validated container systems, and hospital distribution rather than only active pharmaceutical ingredient capacity.

What patents protect micafungin and its formulations?

The historical U.S. patent estate for micafungin was built around the active compound, echinocandin chemistry, pharmaceutical compositions, and therapeutic use. U.S. Patent No. 6,107,458, assigned to Fujisawa Pharmaceutical, is one of the principal early patents associated with micafungin-related compound protection.[2]

The original composition-of-matter and core product protection has expired or reached the end of its effective U.S. term. Current commercial barriers are therefore more likely to arise from:

• Formulation patents.
• Stable liquid formulation patents.
• Container or packaging claims.
• Manufacturing process patents.
• Method-of-use patents.
• Regulatory exclusivity or listed labeling protections.
• Know-how related to sterile manufacturing and stability.

A sodium chloride premix should not be assumed to infringe a historical lyophilized-vial patent merely because it contains the same active ingredient. The relevant analysis requires claim-by-claim review of active-ingredient, concentration, excipient, pH, container, stability, and manufacturing limitations.

How strong is the remaining patent estate?

The core patent position is weaker than it was during the launch period because micafungin is an established small-molecule injectable with generic competition. A new premix could still obtain protection if it demonstrates a specific, non-obvious formulation or packaging solution.

Potentially patentable subject matter includes:

Claim area	Commercial relevance	Likely strength
Micafungin compound	Historically central	Low after expiration
Broad pharmaceutical composition	Broad but vulnerable to prior art	Low to moderate
Micafungin in sodium chloride at defined concentration	Depends on unexpected stability or usability	Moderate if data are strong
Specific pH and stability profile	Can protect a practical formulation	Moderate
Light-protective container system	Potentially narrow	Moderate
Extended room-temperature stability	Commercially valuable	Moderate to strong if unexpected
Manufacturing process	Can protect yield or impurity control	Moderate
Method of treating candidiasis	Usually limited by prior art and clinical labeling	Low to moderate

Patent value would depend on comparative data against the lyophilized reference product and other liquid formulations. Routine substitution of sodium chloride for an established diluent is unlikely to support broad claims without an unexpected technical effect.

What is the FDA status of micafungin and its Orange Book position?

Mycamine was approved by the FDA in 2005 under NDA 021506.[1] The product is a small-molecule injectable, so generic competitors use the ANDA pathway. FDA product labeling identifies the approved strengths and dilution instructions.

The Orange Book is relevant for listed patents and exclusivity associated with the reference drug. The historic core-patent period has ended, and current entry analysis should focus on the live Orange Book listing for the specific reference presentation, any remaining regulatory exclusivity, and the proposed generic’s formulation and labeling.

Are there Paragraph IV risks?

A Paragraph IV certification becomes relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. For a micafungin sodium chloride product, the main Paragraph IV exposure would arise from any still-listed formulation, use, or process patent rather than from the original compound patent.

The commercial significance depends on:

• Whether the patent is listed for the reference product.
• Whether the proposed product uses the claimed concentration or container.
• Whether the generic label includes a protected use.
• Whether the reference sponsor files suit within the statutory period.
• Whether a 30-month stay applies.
• Whether the ANDA applicant can launch at risk.

A patent certification strategy should separate the proposed formulation from the reference label and identify any protected method-of-use language that can be carved out under the ANDA pathway.

When does micafungin lose exclusivity?

Micafungin’s market exclusivity has already moved from innovator control to generic competition in the United States. The relevant distinction is between:

• Core compound patent expiration.
• FDA new chemical entity exclusivity.
• Pediatric exclusivity.
• Listed formulation or method patents.
• Data exclusivity in non-U.S. markets.
• Regulatory barriers to a new ready-to-use presentation.

The precise commercial entry date depends on the individual formulation, ANDA status, patent certifications, and FDA approval timing. Patent expiration dates should be confirmed against the current FDA Orange Book and USPTO records before a launch decision.[3,4]

Outside the United States, European and other national patent, supplementary protection certificate, data-exclusivity, and pricing rules may produce different entry dates. A global launch should not use the U.S. expiration framework as a proxy for Europe, Japan, or emerging markets.

What litigation and settlement issues affect micafungin?

Micafungin litigation risk is likely to be lower for a conventional generic vial than for a differentiated premix. A novel ready-to-use product can create new disputes if it relies on:

• A formulation patent owned by the reference sponsor or another generic company.
• A container patent.
• A manufacturing process patent.
• A stability claim that overlaps an existing patent.
• A label that includes a patented use.

Settlement agreements involving paragraph IV challenges can restrict launch dates, supply terms, authorized-generic arrangements, or formulation development. Any transaction should include a review of public ANDA litigation records, FDA patent certifications, and settlement disclosures filed with the Federal Trade Commission or Department of Justice where applicable.

How does micafungin compare with competing antifungals?

Product	Class	Administration	Premix opportunity	Main competitive issue
Micafungin	Echinocandin	IV	Strong	Generic price pressure and hospital workflow
Anidulafungin	Echinocandin	IV	Moderate	Reconstitution and formulation differentiation
Caspofungin	Echinocandin	IV	Moderate	Established generic competition
Fluconazole	Triazole	Oral and IV	Limited	Low-cost generic and oral substitution
Isavuconazole	Triazole	Oral and IV	Limited to moderate	Higher-value specialty positioning
Liposomal amphotericin B	Polyene	IV	Limited	Toxicity, complex handling, and hospital expertise

Micafungin’s advantage is established echinocandin use with a relatively simple clinical positioning. Its weakness is that an improved container or diluent may be difficult to monetize if hospitals already have efficient pharmacy workflows and multiple generic alternatives.

What revenue exposure and launch scenarios should investors model?

A commercial model should use hospital demand, average selling price, dose wastage, and preparation-cost savings rather than prescription volume alone.

Three launch scenarios are relevant:

Scenario	Product	Market outcome
Standard generic	Lyophilized 50 mg and 100 mg vials	Price-led competition
Differentiated generic	Ready-to-administer sodium chloride premix	Higher price potential with hospital adoption
Premium institutional product	Premix with stronger stability, light protection, and automation compatibility	Narrower market but better margin potential

Revenue exposure is concentrated in inpatient infectious disease, intensive care, oncology, transplant, and pediatric hospitals. Outpatient demand may be limited by the need for intravenous administration and the availability of oral antifungal alternatives in selected indications.

A premix is most commercially defensible where it delivers measurable reductions in pharmacy labor, product waste, or time to treatment. Without these advantages, the product may be treated as another interchangeable generic.

Key Takeaways

• Micafungin in sodium chloride is primarily a formulation and hospital-workflow opportunity.
• The reference product, Mycamine, is a lyophilized vial that requires reconstitution and dilution.
• A ready-to-administer premix could reduce sterile preparation, dosing delays, and waste.
• Sodium chloride, water for injection, pH control, and light-protective packaging are the central design elements.
• Lactose used in the lyophilized reference formulation may not be necessary in an aqueous premix.
• The historical micafungin compound patent estate no longer provides the principal commercial barrier in the United States.
• New patent value would depend on unexpected stability, container compatibility, extended shelf life, or manufacturing advantages.
• The product is regulated as a small-molecule injectable generic, not as a biosimilar.
• Paragraph IV risk is most relevant to surviving formulation, process, container, or method-of-use patents.
• Commercial success depends on hospital procurement economics, not only on lower acquisition price.

FAQs About Micafungin Sodium Chloride Commercialization

Can micafungin be sold as a premixed sodium chloride injection?

Yes. A premixed product would require a formulation that demonstrates adequate stability, sterility, container compatibility, particulate control, and infusion compatibility. The regulatory pathway would depend on the proposed product’s relationship to the reference product and applicable FDA requirements.

Does micafungin sodium chloride require lactose?

Not necessarily. Lactose is associated with the lyophilized reference formulation. A stable aqueous premix may use sodium chloride and water for injection without lactose, subject to formulation and regulatory data.

Is micafungin a biologic requiring biosimilar approval?

No. Micafungin is a small-molecule antifungal drug. Generic versions generally proceed through the ANDA pathway rather than the 351(k) biosimilar pathway.

What patent could protect a micafungin ready-to-use formulation?

A patent could potentially cover a defined micafungin concentration in sodium chloride, a pH range, an unexpected shelf-life profile, a light-protective container, or a manufacturing process. Broad claims would face prior-art and obviousness challenges.

Which hospital segments are most attractive for a micafungin premix?

The strongest targets are transplant centers, oncology hospitals, pediatric institutions, intensive-care units, and facilities with high sterile-compounding costs. These settings have greater potential to value reduced preparation and administration complexity.

References

1. U.S. Food and Drug Administration. (2024). Mycamine (micafungin sodium) for injection: Prescribing information. FDA; Astellas Pharma US, Inc.

2. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,107,458: Echinocandin derivatives. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and patent certification requirements. FDA.

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding—Sterile preparations. United States Pharmacopeial Convention.

6. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.